References

10.1056/nejmra022694

10.1056/nejmra022694 · External reference

10.1097/md.0b013e31803d1764

10.1097/md.0b013e31803d1764 · External reference

10.1016/j.semarthrit.2017.04.001

10.1016/j.semarthrit.2017.04.001 · External reference

10.1002/art.21699

10.1002/art.21699 · External reference

Morphological changes in the large arteries in polymyalgia arteritica

10.1111/j.0954-6820.1972.tb15615.x · 1972 · External reference

Usefulness of 18F-FDG PET-CT for assessing large-vessel involvement in patients with suspected giant cell arteritis and negative temporal artery biopsy

10.1186/s13075-023-03254-w · 2024 · External reference

Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab

10.1002/art.40876 · 2019 · External reference

Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes

10.1002/art.11388 · 2003 · External reference

10.1007/s00259-018-3973-8

10.1007/s00259-018-3973-8 · External reference

10.1097/md.0000000000000622

10.1097/md.0000000000000622 · External reference

10.1136/annrheumdis-2018-213102

10.1136/annrheumdis-2018-213102 · External reference

18F-fluorodeoxyglucose–positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis

10.1002/art.40379 · 2018 · External reference

Is PET/CT essential in the diagnosis and follow-up of temporal arteritis?

10.1016/j.autrev.2017.09.007 · 2017 · External reference

Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy

10.1007/s00259-018-4021-4 · 2018 · External reference

10.1136/ard-2023-224543

10.1136/ard-2023-224543 · External reference

Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and metaanalysis

10.1007/s00259-021-05362-8 · 2021 · External reference

Unresolved reference

External reference

10.7326/0003-4819-120-11-199406010-00004

10.7326/0003-4819-120-11-199406010-00004 · External reference

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis

10.1093/oxfordjournals.qjmed.a068882 · 1994 · External reference

10.1059/0003-4819-155-8-201110180-00009

10.1059/0003-4819-155-8-201110180-00009 · External reference

10.1136/jech-2013-203104

10.1136/jech-2013-203104 · External reference

10.1007/s00296-014-2985-3

10.1007/s00296-014-2985-3 · External reference

10.1136/rmdopen-2020-001417

10.1136/rmdopen-2020-001417 · External reference

[Giant cell arteritis and extratemporal arterial involvement: usefulness of 18FDG positron emission tomography. Concerning 3 case reports and a review of the literature]

10.1016/s0248-8663(02)00620-3 · 2002 · External reference

10.1093/rheumatology/keg317

10.1093/rheumatology/keg317 · External reference

10.1007/s00259-003-1144-y

10.1007/s00259-003-1144-y · External reference

Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides

2004 · External reference

Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT

2011 · External reference

10.1136/ard.2010.149351

10.1136/ard.2010.149351 · External reference

10.1093/rheumatology/ker296

10.1093/rheumatology/ker296 · External reference

10.1016/j.jbspin.2013.06.004

10.1016/j.jbspin.2013.06.004 · External reference

18F-FDG PET/CT in the management of aortitis

10.1097/rlu.0000000000001016 · 2016 · External reference

Repetitive 18F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled disease

10.1016/j.ejim.2017.08.013 · 2017 · External reference

Tocilizumab in giant cell arteritis: a real-life retrospective study

10.1177/0003319717753223 · 2018 · External reference

The role of multimodality imaging in monitoring disease activity and therapeutic response to tocilizumab in giant cell arteritis

10.1155/2020/3203241 · 2020 · External reference

Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients

10.1093/rap/rkaa017 · 2020 · External reference

Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments

10.1093/rheumatology/keab280 · 2022 · External reference

Mycophenolate mofetil in giant cell arteritis

10.3389/fmed.2023.1254747 · 2023 · External reference

Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: a single-centre prospective study

10.1016/j.semarthrit.2023.152174 · 2023 · External reference

[Clinical and paraclinical characteristics and disease course of aortic involvement in giant cell arteritis: 26 cases of aortitis among 63 cases of giant cell arteritis]

10.1016/j.revmed.2013.06.007 · 2014 · External reference

Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis

10.55563/clinexprheumatol/mjm8fr · 2021 · External reference

10.1093/rheumatology/kead215

10.1093/rheumatology/kead215 · External reference

The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters

10.1007/s00259-015-3148-9 · 2016 · External reference

10.3899/jrheum.181222

10.3899/jrheum.181222 · External reference

Persistent FDG uptake in large vessels and risk of relapse in giant cell arteritis

10.1016/j.ejim.2022.08.033 · 2022 · External reference

Atherosclerosis imaging using PET: insights and applications

10.1111/bph.14868 · 2021 · External reference

10.1007/s00259-015-3259-3

10.1007/s00259-015-3259-3 · External reference

Monitoring vasculitis with 18F-FDG PET

2016 · External reference

10.1016/j.atherosclerosis.2021.03.032

10.1016/j.atherosclerosis.2021.03.032 · External reference

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

10.1002/acr.21750 · 2012 · External reference

Outcomes among 196 patients with noninfectious proximal aortitis

10.1002/art.40855 · 2019 · External reference

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the giant cell arteritis Actemra (GiACTA) trial

10.1016/s2665-9913(21)00038-2 · 2021 · External reference